Analysis of associations of polymorphic markers of the CYP2C9, AGTR1, AGT, ACE, CYP11B2 genes with the achievement of target blood pressure values in patients with newly diagnosed arterial hypertension 1-2 degree after 3 weeks of pharmacotherapy with angiotensin II receptor blockers

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Background. The results of numerous pharmacogenetic studies confirm that antihypertensive therapy (AHT) based on the identified polymorphic associations is the most effective and safe.

Objective. Determination of the relationship between the frequency of achieving target blood pressure (BP) values and polymorphic markers CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu), AGTR1 (A1166C), AGT (M235T), ACE (I/D polymorphism), CYP11B2 (C-344T) in patients with newly diagnosed arterial hypertension (AH) 1–2 degree after 3 weeks of AHT with angiotensin II receptor blockers (ARBs).

Methods. The study included 179 patients from the Moscow region with newly diagnosed AH 1-2 degree, 141 (78.8%) women and 38 (21.2%) men aged 32 to 69 years, who were randomly (by simple randomization) assigned to irbesartan and valsartan groups as mono- or combination therapy with hydrochlorothiazide. After 3 weeks of pharmacotherapy, the presence of genetic polymorphism CYP2C9*2 (Arg144Cys), CYP2C9*3 (Ile359Leu), AGTR1 (A1166C), AGT (M235T), ACE (I/D polymorphism), CYP11B2 (C-344T) was determined.

Results. Patients carrying the genotypes C/C AGT C4072T, D/D ACE (I/D polymorphism), T/T CYP11B2 (C-344T) significantly better achieved target BP values after 3 weeks of valsartan pharmacotherapy for newly diagnosed AH 1-2 degree. Patients carrying the genotype I/I ACE (I/D polymorphism) significantly better achieved target BP values after 3 weeks of irbesartan pharmacotherapy.

Conclusion. In order to personalize the initial AHT with ARBs in patients with newly diagnosed AH 1–2 degree, it is recommended to include polymorphic markers AGT (M235T), ACE (I/D polymorphism), CYP11B2 (C-344T) in the genetic panel.

Толық мәтін

Рұқсат жабық

Авторлар туралы

E. Rebrova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Хат алмасуға жауапты Автор.
Email: katrina1987@rambler.ru
ORCID iD: 0000-0002-4374-9754

Cand. Sci. (Med.), Associate Professor, Associate Professor at the Department of Clinical Pharmacology and Propaedeutics of Internal Medicine

Ресей, Moscow

E. Shikh

.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: katrina1987@rambler.ru
ORCID iD: 0000-0001-6589-7654
Ресей, Moscow

Әдебиет тізімі

  1. Franczyk B., Rysz J., Gluba-Brzozka A. Pharmacogenetics of Drugs Used in the Treatment of Cancers. Genes (Basel). 2022;13(2):311. doi: 10.3390/genes13020311.
  2. Rahman F., Muthaiah N., Kumaramanickavel G. Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension. Indian J Pharmacol. 2021;53(4):301–9. doi: 10.4103/ijp.IJP_593_19.
  3. Eadon M.T., Maddatu J., Moe S.M., et al. Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney 360. 2022;3(2):307–16. doi: 10.34067/kid.0005362021.
  4. Al-Hussaniy H.A., Hassan A.F., Oraibi A.I., et al. Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq. J Pharm Bioallied Sci. 2023;15(3):101–6. doi: 10.4103/jpbs.jpbs_313_23.
  5. Katsukunya J.N., Soko N.D., Naidoo J., et al. Pharmacogenomics of Hypertension in Africa: Paving the Way for a Pharmacogenetic-Based Approach for the Treatment of Hypertension in Africans. Int J Hypertens. 2023;2023:9919677. doi: 10.1155/2023/9919677.
  6. Coons J.C., Crisamore K., Adams S., et al. A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension. Ther Adv Respir Dis. 2021;15:17534666211013688. doi: 10.1177/17534666211013688.
  7. Magavern E.F., Kapil V., Saxena M., et al. Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy. Arterioscler Thromb Vasc Biol. 2024;44(4):784–93. doi: 10.1161/ATVBAHA.123.319220.
  8. Реброва Е.В., Ших Е.В. Влияние инсерционно-делеционного полиморфизма гена ангиотензинпревращающего фермента на эффективность антигипертензивной терапии блокаторов рецептора ангиотензина II. Фармация и фармакология. 2023;11(6):494–508. [Rebrova E.V., Shikh E.V. Effect of insertion/deletion polymorphism of angiotensin-converting enzyme gene on efficacy of antihypertensive therapy with angiotensin II receptor blockers. Pharm Pharmacol. 2023;11(6):494–508. (In Russ.)]. doi: 10.19163/2307-9266-2023-11-6-494-508.
  9. Freel E.M., Ingram M., Friel E.C., et al. Phenotypic consequences of variation across the aldosterone synthase and 11-beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study. Clin Endocrinol (Oxf). 2007;67(6):832–8. doi: 10.1111/j.1365-2265.2007.02971.x.
  10. Davies E., Holloway C.D., Ingram M.C., et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension. 1999;33(2):703–7. doi: 10.1161/01.hyp.33.2.703.
  11. Lacchini R., Sabha M., Coeli F.B., et al. T allele of -344 C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension. Hypertens Res. 2009;32(2):159–62. doi: 10.1038/hr.2008.36.
  12. Kurland L., Melhus H., Karlsson J., et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: Results from the swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) trial. Am J Hypertens. 2002;15(5):389–93. https://doi.org/10.1016/S0895-7061(02)02256-2.
  13. Ji X., Qi H., Li D.B., et al. Associations between human aldosterone synthase CYP11B2 (-344T/C) gene polymorphism and antihypertensive response to valsartan in Chinese patients with essential hypertension. Int J Clin Exp Med. 2015;8(1):1173–7.
  14. Ortlepp J.R., Hanrath P., Mevissen V., et al. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol. 2002;445(1–2):151–2. doi: 10.1016/s0014-2999(02)01766-1.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. 1. Frequency of achieving target BP values ​​after 3 weeks of AHT in irbesartan/valsartan patient groups depending on the AGT C4072T genotype

Жүктеу (66KB)
Метадеректер
3. Fig. 2. Frequency of achieving target BP values ​​after 3 weeks of AHT in irbesartan/valsartan patient groups depending on the ACE genotype (I/D polymorphism)

Жүктеу (66KB)
Метадеректер
4. Fig. 3. Frequency of achieving target BP values ​​after 3 weeks of AHT in irbesartan/valsartan patient groups depending on the CYP11B2 C344T genotype

Жүктеу (67KB)
Метадеректер

© Bionika Media, 2024